background and purpose: the clinical outcome of intrauterine insemination (iui) treatment cycles employing a gonadotrophin-releasing hormone agonist [superfact)] or human chorionic gonadotrophin (hcg) for ovulation induction was compared. materials and methods: a group of 100 patients presenting with amenorrhoea, oligomenorrhoea or unexplained infertility were all treated with clomiphene 100 mg...

Purpose The potential effect of gonadotropin-releasing hormone agonist (GnRHa) treatment on the weight of girls with central precocious puberty (CPP) remains a controversy. We investigated anthropometric changes during and after GnRHa treatment among girls with CPP. Methods This retrospective study evaluated data from 127 girls with CPP who received GnRHa treatment for ≥2 years. Height, weigh...

background: endometriosis is a common gynecological problem associated with chronic pelvic pain. objective: to evaluate the effectiveness of current hormonal treatments of endometriosis associated pain. materials and methods: randomized controlled studies identified from databases of medline and cochrane systemic review groups were pooled. 7 rcts were recruited for evaluation in this review. da...

INTRODUCTION The aim was to compare the efficacy of long-acting and short-acting gonadotropin-releasing hormone (GnRH) agonists by long protocol on embryo quality, endometrial thickness and pregnancy rate in in vitro fertilization. MATERIAL AND METHODS In this retrospective study, long-term pituitary downregulation, achieved with long- and short-acting GnRH agonists (GnRHa), was performed for...

The evidence of the efficacy of preoperative medical treatment with danazol, gonadotrophin releasing-hormone agonists (GnRHa) or progestins in facilitating surgery and improving the long-term results of myomectomy, hysteroscopic metroplasty and endometrial resection has been reviewed. Sixteen randomized and non-randomized controlled clinical trials, published in the English literature between 1...

Gonadotropin-releasing hormone analog (GnRHa) is used for medical management of endometriosis and premature luteinizing hormone surge during controlled ovarian stimulation. Human endometrium expresses GnRH receptors, and GnRHa alters the expression of transforming growth factor-beta (TGF-beta) and receptors in endometrial cells. Because the diverse biological actions of GnRHa and TGF-beta are m...

To evaluate the incidence and characteristics of uterine bleeding during postoperative gonadotropin-releasing hormone agonist (GnRHa) treatment combined with the lowest effective dose of estrogen-progestogen add-back therapy in Chinese women of reproductive age with endometriosis. Seventy Chinese women aged 18 to 50 years with stage III or IV endometriosis and treated with postoperative GnRHa a...

Utero-ovarian arterial blood flow and hormonal profile were evaluated in 20 patients with polycystic ovary syndrome (PCOS) and in 22 patients with normal menstrual cycle (NMC) undergoing in-vitro fertilization (IVF) treatment. In this controlled prospective clinical study the vascular impedance in the utero-ovarian arteries was measured in both groups on days 4, 13, 22 [introduction of gonadotr...

Luo, Xiaoping, Li Ding, and Nasser Chegini. Gonadotropinreleasing hormone and TGFactivate MAP kinase and differentially regulate fibronectin expression in endometrial epithelial and stromal cells. Am J Physiol Endocrinol Metab 287: E991–E1001, 2004. First published July 20, 2004; doi:10.1152/ajpendo.00200.2004.—Gonadotropin-releasing hormone analog (GnRHa) is used for medical management of endo...